For Q1 FY2026 (ended March 31, 2026), Olema Pharmaceuticals reported no revenue. Net loss was $53.1 million, a 74.7% increase year-over-year. Operating loss was $58.0 million, up 66.3% from the prior year. Diluted EPS was -$0.52, a 44.4% decline. Cash and cash equivalents stood at $52.5 million, with total equity of $480.5 million.
•No revenue reported for Q1 FY2026.
•Net loss widened 74.7% YoY to $53.1 million.
•Operating loss increased 66.3% YoY to $58.0 million.
•Diluted EPS of -$0.52, down 44.4% from prior year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer.
Its portfolio also includes OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer, and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and solid tumor cancers. Incorporated in 2006 and headquartered in San Francisco, California, Olema Pharmaceuticals was formerly known as CombiThera, Inc. before rebranding in March 2009.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women's cancers. Its lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and selective ER degrader, currently in Phase 3 clinical trials for recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The company is also evaluating palazestrant in combination with CDK4/6 inhibitors, a PI3Kα inhibitor (alpelisib), an mTOR inhibitor, and a CDK4 inhibitor in Phase 1b/2 trials for ER+/HER2- advanced or metastatic breast cancer. Additionally, Olema is developing OP-3136, an orally-available small molecule that inhibits KAT6, currently in Phase 1 trials for breast and solid tumor cancers.
On which stock exchange is Olema Pharmaceuticals (OLMA) listed and what currency is used?
Olema Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol OLMA. The company's financials are reported in US Dollars (USD), as it is headquartered in the United States. Trading on NasdaqGS provides liquidity and visibility among institutional and retail investors, and the use of USD aligns with the company's operations and reporting standards.
What sector and industry does Olema Pharmaceuticals (OLMA) belong to?
Olema Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative therapies for women's cancers, particularly breast cancer. Biotechnology companies like Olema engage in research and development of drugs based on biological processes, often targeting specific molecular pathways. This industry is characterized by high R&D costs, regulatory milestones, and potential for significant returns upon successful product commercialization.
Where is Olema Pharmaceuticals (OLMA) headquartered and what is its history?
Olema Pharmaceuticals is headquartered in San Francisco, California, United States. The company was incorporated in 2006 and was originally known as CombiThera, Inc. before rebranding to Olema Pharmaceuticals in March 2009. Its focus on women's cancers, particularly ER+/HER2- breast cancer, reflects its strategic location in a major biotech hub, which provides access to talent, research collaborations, and funding opportunities.
What is the business model of Olema Pharmaceuticals (OLMA) and how does it generate revenue?
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company, meaning it has not yet generated revenue from product sales. Its business model centers on discovering and developing novel therapies for women's cancers, with the goal of eventually commercializing them. The company's lead candidate, palazestrant, is in Phase 3 trials for ER+/HER2- metastatic breast cancer, and it is also exploring combinations with other agents. Additionally, Olema is developing OP-3136, a KAT6 inhibitor in Phase 1 trials. Revenue, if any, would come from future product sales, licensing agreements, or partnerships. Currently, the company funds operations through equity financing, grants, or collaborations.